RhumbLine Advisers
GPCR icon

RhumbLine Advisers’s Structure Therapeutics GPCR Stock Holding History

RhumbLine Advisers’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-450
Closed -$9.33K – 4153
2025
Q2 		$9.33K Hold
450
– – ﹤0.01% 3869
2025
Q1 		$7.79K Hold
450
– – ﹤0.01% 3867
2024
Q4 		$12.2K Hold
450
– – ﹤0.01% 3859
2024
Q3 		$19.8K Hold
450
– – ﹤0.01% 3816
2024
Q2 		$17.7K Hold
450
– – ﹤0.01% 3889
2024
Q1 		$19.3K Hold
450
– – ﹤0.01% 3767
2023
Q4 		$18.3K Buy
+450
New +$25.8K ﹤0.01% 3785

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's GPCR Position: Q3 2025 in Review

RhumbLine Advisers sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 450 shares — an estimated $9.33K sold.

RhumbLine Advisers first reported a position in GPCR in Q4 2023 and held it in 7 quarters. The position peaked at $19.8K in Q3 2024. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

  • RhumbLine Advisers reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 450 Structure Therapeutics shares in Q3 2025, an estimated $9.33K.
  • RhumbLine Advisers first reported a position in Structure Therapeutics in Q4 2023 and held it in 7 quarters.
  • RhumbLine Advisers's Structure Therapeutics position peaked at $19.8K in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.